Search clinical trials for: ventavis

Total 50 results

Yonsei University

Not yet recruiting

Effects of Iloprost on Oxygenation During One-lung Ventilation in Supine-positioned Patients

Mediastinal Mass

Korea, Republic of
National Cancer Institute (NCI)

Withdrawn

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Chronic Obstructive Pulmonary Disease | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Tobacco-Related Carcinoma | Bronchial Epithelial Dysplasia

United States
Duke University
Actelion

Terminated

Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension (OVATION)

Pulmonary Hypertension

United States
University of Oklahoma

Completed

Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD) (Iloprost)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States
National Cancer Institute (NCI)

Completed

Iloprost in Preventing Lung Cancer in Former Smokers

Lung Carcinoma

United States
Bayer

Completed

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

Hypertension, Pulmonary

Japan
Hamad Medical Corporation

Completed

Inhaled Iloprost for Suspected COVID-19 Respiratory Failure (ILOCOVID)

COVID-19 | ARDS, Human | Hypoxemic Respiratory Failure

Qatar
Bayer

Completed

Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension (VENTASTEP)

Hypertension, Pulmonary

Germany
Bayer

Completed

Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years (OPTION)

Pulmonary Hypertension

Turkey
Actelion

Terminated

The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension (VISION)

Pulmonary Hypertension

United States
Bayer

Completed

Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension (IVENT)

Hypertension, Pulmonary

Russian Federation
Bayer

Completed

Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)

Pulmonary Arterial Hypertension

Germany, Austria
Actelion
Canadian Heart Research Centre

Completed

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program (PAH QuERI Ext)

Pulmonary Arterial Hypertension

United States, Puerto Rico
Bayer

Completed

Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (COMPHI)

Pulmonary Hypertension

Portugal
Bayer

Completed

Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study (IBUKI)

Hypertension, Pulmonary

Japan
Bayer

Completed

Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients (DAILY)

Pulmonary Arterial Hypertension

France
Bayer

Completed

Efficacy of Ventavis Used in Real-life Setting. (SPHERA)

Pulmonary Arterial Hypertension

Poland
Bayer

Completed

Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20) (VENTASWITCH)

Hypertension, Pulmonary

Germany
Louisiana State University Health Sciences Center...

Completed

Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients

Chronic Obstructive Pulmonary Disease

United States
Shanghai Jiao Tong University School of Medicine
Cardiothoracic Surgical Group of Chinese Society of Pediatric Surgery

Completed

Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD)

Pulmonary Hypertension

China
United Therapeutics

Completed

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies (Aspire)

Pulmonary Arterial Hypertension

United States
Actelion

Terminated

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Spain, France
Actelion

Completed

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension (PROWESS 15 Ext)

Pulmonary Arterial Hypertension

United States, Germany, Austria
Actelion

Completed

Iloprost Power 15 in Pulmonary Arterial Hypertension (PROWESS 15)

Pulmonary Arterial Hypertension

United States, Austria, Germany
Meshalkin Research Institute of Pathology of Circulation

Unknown

Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension

Residual Pulmonary Hypertension

Russian Federation
Actelion

Terminated

Ventavis® Registry Protocol (RESPIRE)

Pulmonary Arterial Hypertension

United States
Bayer

Completed

Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years

Hypertension, Pulmonary

Italy, Spain, France, Germany, Portugal, United Kingdom
University of California, Los Angeles
Actelion

Terminated

Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

Pulmonary Arterial Hypertension | Congenital Heart Disease | Eisenmenger's Syndrome

United States
Seattle Children's Hospital
Actelion

Withdrawn

Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients

Pulmonary Hypertension | Acute Respiratory Distress Syndrome | Congenital Heart Defects | Neonatal Hypoxic Respiratory Failure | Persistent Pulmonary Hypertension of Newborn
Bayer
Dra. Pilar Escribano Subías - Coordinator - HU 12 de Octubre - Madrid (Spain)

Completed

Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System (Inventa)

Pulmonary Arterial Hypertension

Spain
Duke University

Terminated

Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide

Pulmonary Hypertension
University of Chicago

Terminated

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

Pulmonary Hypertension

Israel, United States
University of Cincinnati

Completed

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Pulmonary Arterial Hypertension | Sarcoidosis

United States
Actelion

Terminated

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Pulmonary Hypertension

United States
Actelion

Terminated

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension (INHALE-15)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

Pulmonary Arterial Hypertension

United States
Ludwig-Maximilians - University of Munich
Algora

Completed

Iloprost in High Risk Cardiac Surgical Patients (Ilocard)

Pulmonary Hypertension

Germany
Heidelberg University

Completed

Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery

Pulmonary Hypertension

Germany
University of Oklahoma
Actelion

Completed

Iloprost Effects on Gas Exchange and Pulmonary Mechanics

Pulmonary Hypertension | Acute Respiratory Distress Syndrome | Acute Lung Injury

United States
Shanghai Jiao Tong University School of Medicine

Completed

Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease

Pulmonary Hypertension

China
Vanderbilt University
Actelion

Completed

Inhaled Iloprost in Mild Asthma

Asthma

United States
Bayer

Completed

Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)

Pulmonary Hypertension

Korea, Republic of
Carmel Medical Center

Unknown

Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) (COPDVEN)

Chronic Obstructive Pulmonary Disease

Israel
Bayer

Completed

Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

Hypertension, Pulmonary

Belgium, France, Spain, Netherlands, Italy, Portugal, Poland
Actelion

Withdrawn

Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Actelion

Completed

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis | Pulmonary Hypertension

United States
Bayer

Completed

Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension

Hypertension, Pulmonary
Bayer

Completed

Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)

Primary Hypertension

China
VA Loma Linda Health Care System
Actelion

Unknown

Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude

Hypoxic Pulmonary Vasoconstriction

United States
United Therapeutics

Terminated

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Hypertension, Pulmonary

United States

3

Subscribe